Sven Francque - Concepedia

Author

Sven Francque

Also Known As

Amalia Gastaldelli, Francque, Sven, Javier Castell, Jian Zheng, Jérôme Boursier, L Gilligan, Maria Redondo, Peter Stärkel, S Francque, S M Francque

447

Publications

33.1K

Citations

H-Index

116

Concepts

All Affiliations

Antwerp University Hospital University of Antwerp Inserm Newcastle University Sorbonne Université

About

Sven Francque is an author at Antwerp University Hospital specializing in medicine, hepatology, and liver physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	36	50	9.3K
2	Health Sciences	27	34	7K
3	Public Health	4	4	196
4	Nursing	1	1	32
5	Biochemistry	1	1	27

Sven Francque

140

Publications

20.6K

Citations

H-Index

Page 1

	Year	Citations
A multisociety Delphi consensus statement on new fatty liver disease nomenclature Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu, Hepatology Evidence-based MedicinePathologyFatty Liver DiseaseObesityMetabolic Syndrome	2023	2.5K
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis Stephen A. Harrison, Pierre Bédossa, Cynthia D. Guy, New England Journal of Medicine	2024	1.4K
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, Journal of Hepatology ObesityMetabolic SyndromeMetabolic Associated SteatohepatitisHepatologyMetabolic Associated Steatotic Liver Disease	2024	1.2K
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Zobair M. Younossi, Vlad Ratziu, Rohit Loomba, The Lancet Interim AnalysisMetabolic Associated SteatohepatitisHepatologyPlacebo-controlled Phase 3Nonalcoholic Fatty Liver Disease	2019	1.2K
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening Vlad Ratziu, Stephen A. Harrison, Sven Francque, Gastroenterology	2016	993
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis Stuart McPherson, Timothy Hardy, Jean‐François Dufour, The American Journal of Gastroenterology	2016	844
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH Sven Francque, Pierre Bédossa, Vlad Ratziu, New England Journal of Medicine	2021	655
A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis Scott L. Friedman, Vlad Ratziu, Stephen A. Harrison, Hepatology	2017	646
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease Yang‐Lin Liu, Helen L. Reeves, Alastair D. Burt, Nature Communications	2014	601
Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆ Quentin M. Anstee, Rebecca Darlay, Simon Cockell, Journal of Hepatology	2020	493

Page 1